S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
What’s At Stake In April is Shocking (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
Stocks are for suckers – try this instead (Ad)
UN body mulls deep sea mining amid demand for minerals
Credit Suisse takeover hits heart of Swiss banking, identity
Stocks are for suckers – try this instead (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
What’s At Stake In April is Shocking (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
Stocks are for suckers – try this instead (Ad)
UN body mulls deep sea mining amid demand for minerals
Credit Suisse takeover hits heart of Swiss banking, identity
Stocks are for suckers – try this instead (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
What’s At Stake In April is Shocking (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
Stocks are for suckers – try this instead (Ad)
UN body mulls deep sea mining amid demand for minerals
Credit Suisse takeover hits heart of Swiss banking, identity
Stocks are for suckers – try this instead (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
Canada approves largest telecom deal in country's history
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
What’s At Stake In April is Shocking (Ad)pixel
MarketBeat Week in Review – 3/27 - 3/31
UK travelers face hours-long waits for ferries to France
Stocks are for suckers – try this instead (Ad)
UN body mulls deep sea mining amid demand for minerals
Credit Suisse takeover hits heart of Swiss banking, identity
Stocks are for suckers – try this instead (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
Canada approves largest telecom deal in country's history
NASDAQ:BBIO

BridgeBio Pharma - BBIO Earnings Date, Estimates & Call Transcripts

$16.58
-0.57 (-3.32%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$16.41
▼
$17.80
50-Day Range
$8.52
▼
$18.55
52-Week Range
$4.98
▼
$19.94
Volume
2.59 million shs
Average Volume
6.16 million shs
Market Capitalization
$2.51 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.33

Earnings Summary

Upcoming
Earnings Date
May. 4Estimated
Actual EPS
(Feb. 23)
-$0.87 Missed By -$0.01
Consensus EPS
(Feb. 23)
-$0.86
Last Year's Q1 EPS
(2/24/2022)
-$1.01
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

BBIO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

BBIO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

BridgeBio Pharma Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($0.88)($0.86)($0.87)
Q2 20232($0.86)($0.86)($0.86)
Q3 20232($0.86)($0.75)($0.81)
Q4 20232($0.86)($0.74)($0.80)
FY 20238($3.46)($3.21)($3.34)

BBIO Earnings Date and Information

BridgeBio Pharma last issued its quarterly earnings results on February 23rd, 2023. The reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.86) by $0.01. The firm earned $1.87 million during the quarter, compared to the consensus estimate of $12.24 million. BridgeBio Pharma has generated ($3.27) earnings per share over the last year (($3.27) diluted earnings per share). Earnings for BridgeBio Pharma are expected to grow in the coming year, from ($3.13) to ($2.44) per share. BridgeBio Pharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 4th, 2023 based off prior year's report dates.

BridgeBio Pharma Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/4/2023
(Estimated)		        
2/23/2023Q4 2022($0.86)($0.87)($0.01)($0.82)$12.24 million$1.87 million
11/3/2022Q3 2022($1.02)($0.93)+$0.09($0.93)$6.26 million$0.34 million
8/4/2022Q2 2022($0.92)($0.81)+$0.11($1.55)$29.96 million$73.75 million
5/5/2022Q1 2022($1.13)($1.19)($0.06)($1.03)$4.47 million$1.69 million
2/24/2022Q4 2021($0.83)($1.01)($0.18)($1.01)$21.58 million$12.89 million    
11/4/20219/30/2021($0.91)($1.06)($0.15)($1.06)$16.12 million$2.34 million
8/5/20216/30/2021($0.97)($0.66)+$0.31($0.66)$24.93 million$54.00 million
5/6/20213/31/2021($0.83)($1.18)($0.35)($1.18)$21.91 million$0.46 million  
2/24/202112/31/2020($0.86)($1.01)($0.15)($1.01)$15.34 million$0.12 million
11/5/20209/30/2020($0.90)($0.98)($0.08)($0.98)$17.25 million$8.13 million  
8/11/20206/30/2020($0.76)($1.03)($0.27)($1.03)
5/13/2020Q1 2020($0.6890)($0.78)($0.0910)($0.78)
3/2/202012/31/2019($0.70)($0.62)+$0.08($0.62)$13.82 million
11/7/2019Q3($0.55)($0.51)+$0.04($0.51)$26.74 million












BridgeBio Pharma Earnings - Frequently Asked Questions

When is BridgeBio Pharma's earnings date?

BridgeBio Pharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 4th, 2023 based off last year's report dates. Learn more on BBIO's earnings history.

Did BridgeBio Pharma beat their earnings estimates last quarter?

In the previous quarter, BridgeBio Pharma (NASDAQ:BBIO) missed the analysts' consensus estimate of ($0.86) by $0.01 with a reported earnings per share (EPS) of ($0.87). Learn more on analysts' earnings estimate vs. BBIO's actual earnings.

How much revenue does BridgeBio Pharma generate each year?

BridgeBio Pharma (NASDAQ:BBIO) has a recorded annual revenue of $77.65 million.

How much profit does BridgeBio Pharma generate each year?

BridgeBio Pharma (NASDAQ:BBIO) has a recorded net income of -$481.18 million. BBIO has generated -$3.27 earnings per share over the last four quarters.

What is BridgeBio Pharma's EPS forecast for next year?

BridgeBio Pharma's earnings are expected to grow from ($3.13) per share to ($2.44) per share in the next year.

More Earnings Resources from MarketBeat

Earnings Tools:
Earnings By Country:
Latest Articles:
Upcoming Earnings:
This page (NASDAQ:BBIO) was last updated on 4/1/2023 by MarketBeat.com Staff